Press Release
Charles Howenstine DDS on Why Dentistry Should Focus More on Arresting Disease Than Repairing Damage
Michigan, USA, 25th March 2026, ZEX PR WIRE — In modern dentistry, many conversations focus on repairing damage. Fillings replace decay, crowns restore broken teeth, and advanced procedures address long-standing oral health issues. While these treatments remain important, some dentists believe the profession should place far greater emphasis on a different concept: arresting disease before it progresses.
Charles Howenstine DDS, a Stevensville, Michigan dentist and practice owner, believes that one of the most important shifts in dental care is recognizing the power of early intervention and preventive strategies designed to arrest dental disease.
“In dentistry, the word ‘arrest’ has a very specific meaning,” says Dr. Howenstine. “When we say a condition is arrested, we mean the disease process has stopped progressing. The damage is no longer actively spreading.”
This concept can apply to several common oral health issues. For example, an arrested caries lesion refers to tooth decay that is visible but no longer actively damaging the tooth. The bacteria responsible for the decay are no longer progressing deeper into the enamel or dentin. Similarly, early gum inflammation can sometimes be managed in ways that arrest the progression toward more severe periodontal disease.
According to Dr. Howenstine, focusing on arresting disease early can significantly change how patients experience dental care.
A Shift From Reaction to Prevention
Dr. Howenstine’s perspective comes from an unusual professional background that includes both finance and dentistry. Raised in Rice Lake, Wisconsin, he graduated from Rice Lake High School in 1999 and earned a Finance degree from Marquette University in 2003. After working at Capstone Investments, he later returned to school through the University of Wisconsin, Milwaukee and completed dental training at the Marquette University School of Dentistry in 2011.
That early experience in finance shaped how he evaluates risk and long-term outcomes.
“In finance, small problems can grow quickly if they aren’t addressed early,” he explains. “Dental disease works in a very similar way. If you can arrest the issue early, you prevent much larger consequences later.”
Following graduation from dental school, Dr. Howenstine practiced in Wisconsin with Midwest Dental in Kimberly before relocating to Stevensville, Michigan in 2012 to purchase and operate his own dental practice.
Since then, his clinical approach has focused on identifying early warning signs of oral health problems and applying treatment strategies that arrest disease progression before extensive repair becomes necessary.
The Science Behind Arrested Dental Disease
Dental research increasingly supports the idea that many oral health conditions can be stabilized when identified early.
Tooth decay, for example, is not always an unstoppable process. In its early stages, enamel demineralization can sometimes be reversed or stabilized through improved oral hygiene, fluoride exposure, dietary changes, and professional dental monitoring.
When those steps are successful, the decay may remain visible but inactive. In clinical terms, the lesion becomes arrested.
The same principle applies to gum disease. Early gum inflammation, also known as gingivitis, can often be arrested through improved oral hygiene practices and routine dental care before it progresses to periodontitis, a more severe condition that damages the bone supporting the teeth.
Dr. Howenstine believes the dental profession should talk more openly about these possibilities.
“Patients often think dentistry is only about fixing things once they break,” he says. “But many dental problems can be arrested long before they require major procedures.”
Communication as a Clinical Tool
One of the key elements of Dr. Howenstine’s practice philosophy is straightforward communication.
He believes patients make better decisions when they clearly understand their oral health status and the steps that can arrest disease progression.
“A lot of dentistry comes down to communication,” he explains. “If patients understand what early decay looks like, or what early gum inflammation means, they can take steps that help keep those problems arrested.”
This approach also emphasizes realistic treatment planning. Instead of rushing toward complex procedures, the goal is often to stabilize the condition first and monitor it over time.
Short visits, consistent monitoring, and patient education can make a significant difference.
“Small interventions done consistently can keep a lot of dental problems arrested,” Dr. Howenstine notes.
A Practical Philosophy for Modern Dentistry
Running a dental practice also requires balancing clinical care with operational discipline. Since purchasing his Stevensville practice in 2012, Dr. Howenstine has applied the same methodical approach to practice management that he applies to dentistry.
Clear documentation, structured workflows, and consistent routines help support both staff and patients.
These systems allow the practice to maintain accurate records, coordinate care effectively, and follow up on conditions that require monitoring to ensure they remain arrested.
“Consistency matters,” he says. “Whether it’s patient care or practice operations, the goal is to identify issues early and keep them from becoming larger problems.”
Beyond the Dental Chair
Dr. Howenstine’s personal interests reflect the same mindset that shapes his professional philosophy. Over the years, he has participated in varsity hockey and soccer, trained for half marathons, crewed on a racing sailboat, and competed in long-distance cross-country ski races.
These activities emphasize preparation, discipline, and endurance.
In many ways, those principles mirror the concept of arresting dental disease.
“Long-distance sports teach you that small habits repeated every day lead to better results,” he says. “The same is true for oral health.”
Regular brushing, flossing, and dental visits may seem simple, but those habits can arrest the early stages of dental disease and prevent much more complex problems later.
Rethinking the Future of Dentistry
As dental technology continues to advance, treatments will undoubtedly become more sophisticated. Yet Dr. Howenstine believes the most meaningful progress in dentistry may come from shifting the focus toward prevention and early intervention.
Rather than waiting for damage to become severe enough to require extensive procedures, dentists and patients can work together to arrest disease before it progresses.
“Dentistry doesn’t always have to be about repairing damage,” he says. “Often the best outcome is when we arrest the problem early and never let it reach that point.”
For patients, that philosophy can translate into fewer complex procedures, lower long-term costs, and healthier smiles that last for decades.
For the dental profession, it may represent a renewed focus on one of the field’s most powerful tools: prevention.
As Dr. Howenstine puts it, “If we can arrest dental disease early, we can change the entire trajectory of oral health.”
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Nova Junk, a family-owned junk removal company based in Alexandria, Virginia, celebrates two decades of responsible hauling, recycling, and donation services across the Washington DC metro region.
Washington, United States, 16th Jul 2026 – Nova Junk, a locally owned junk removal company serving Washington, DC, Northern Virginia, and Maryland, is marking its 20th year in business. Founded on September 11, 2005, according to information published on the company website, the company has grown from a two-person family operation into a multi-service hauling company with a team that includes extended family members and long-tenured employees.
Nova Junk provides junk removal, estate cleanouts, office cleanouts, construction debris removal, yard debris hauling, shed removal, hot tub disposal, and labor-only services, according to the company website. The company serves communities throughout the Washington DC metro area, including Alexandria, Fairfax, Arlington, Bethesda, Montgomery County, and Prince George County.
A distinguishing feature of Nova Junk’s operating model is its three-stage disposal process: donate, recycle, and landfill. According to information published on the company website, the team sorts through all collected material, first setting aside items that can be donated to local charities and then separating recyclable materials such as batteries, printers, and refrigerators. Only the remainder goes to the landfill, and the company states that it typically sends just one third of collected material to the dump.
The company is licensed and fully insured, according to the company website, and places a strong emphasis on punctuality and transparent pricing. Nova Junk states that final charges are adjusted downward when a load turns out to be smaller than estimated, a policy highlighted repeatedly in customer reviews published on the company website.
“We started this company as a family and grew it the same way – by treating every customer’s home and business the way we would want ours treated,” said Norman Elbekri, Co-founder at Nova Junk. “After 20 years we are still committed to the same values we started with: honest pricing, responsible disposal, and service that people can count on.”
Nova Junk serves both residential and commercial clients. Services extend to de-cluttering and hoarding solutions, moving and foreclosure cleanouts, and demolition site cleanup. The company operates from two locations – 2000 Duke Street in Alexandria, Virginia and Smoketown Road in Woodbridge, Virginia – and can be reached at novajunk.com.
About Nova Junk
Nova Junk is a family-owned junk removal company founded in 2005, serving Washington, DC, Northern Virginia, and Maryland. The company provides residential and commercial hauling, estate cleanouts, construction debris removal, and specialty services including shed and hot tub removal. Nova Junk is committed to responsible disposal through a donate-recycle-landfill approach that minimizes landfill impact. Learn more at https://www.novajunk.com
Media Contact
Organization: Nova Junk
Contact Person: Norman Elbekri Co-founder
Website: https://www.novajunk.com/
Email:
info@novajunk.com
City: Washington
Country:United States
Release id:47175
The post Nova Junk marks 20 years of eco-friendly junk removal in the Washington DC area appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Jyong Biotech has updated its market entry strategy for innovative botanical pharmaceuticals, establishing multiple competitive advantages for its new drug portfolio
Jyong Biotech Ltd. (Nasdaq stock code: MENS) (hereinafter referred to as “the Company” or “Jyong Biotech”) is a science-driven biotechnology company dedicated to developing and commercializing innovative plant-based therapies. The Company recently announced that, following an analysis of the clinical efficacy and competitive advantages of its innovative botanical drugs Botreso® and PCP, it has advanced its market access strategy.
As previously announced by the company, its first core product, Botreso®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan, while its second core product, PCP, has successfully completed a Phase II clinical trial. Overall clinical data demonstrate that Jyong Biotech’s innovative botanical drugs exhibit significant differentiation advantages compared to currently marketed synthetic chemical drugs.
Overall Safety Profile for Long-Term Use
For middle-aged and elderly males requiring long-term medication, safety is one of the most decisive factors. In clinical trials—Botreso® (Phase III) had a treatment duration of one year, while PCP (Phase II) lasted two years—no drug-related serious adverse events were observed, demonstrating excellent safety and tolerability.
In contrast, currently available chemically synthesized drugs for the treatment of benign prostatic hyperplasia (BPH) are often associated with adverse effects such as postural hypotension, erectile dysfunction, and decreased libido. Regulatory authorities and research institutions have linked certain synthetic alternative medications to significant risks, prompting the U.S. Food and Drug Administration (FDA) to issue a safety advisory regarding advanced prostate cancer and depression in 2011, and to include suicidal ideation in its list of adverse reactions in 2022. Additionally, an independent study conducted in 2021 also established associations between these drugs and cardiac failure.
Management of risks associated with advanced prostate cancer
Large-scale international clinical trials have demonstrated that while certain synthetic drugs used to treat benign prostatic hyperplasia (BPH) can reduce the overall incidence of prostate cancer, they may paradoxically increase the proportion of advanced prostate cancer (Grisson score ≥ 7) when cancer develops, thereby posing significant clinical safety concerns.
The Phase II clinical trial of PCP was a large-scale, long-term study on rare conditions conducted in Taiwan across 20 major hospitals. Over a period of two years, the trial involved 135 urologists (representing more than one-tenth of all urologists in Taiwan) and enrolled a total of 702 participants. It was one of the first global clinical trials specifically targeting prostate cancer prevention using a novel botanical drug conducted in Taiwan. The results demonstrated that PCP exhibited a downward trend in both overall prostate cancer incidence and the risk of advanced-stage prostate cancer, effectively addressing concerns within the medical community regarding the risks associated with existing therapies.
Comprehensive approach of “Treatment + Prevention + Metabolic Management”
Based on the clinical data from the company’s conducted trials, the company believes it is establishing a differentiated product positioning.
• Improvement of lower urinary tract symptoms (LUTS): Effectively alleviates symptoms associated with benign prostatic hyperplasia.
• Prevention of prostate cancer: Demonstrates prophylactic clinical potential.
• Metabolic and cardiovascular protection: Decreased triglyceride levels (P=0.05), significantly reduced total cholesterol and low-density lipoprotein (bad cholesterol) (P<0.05), significantly increased high-density lipoprotein (good cholesterol) (P<0.05), and maintained stable blood glucose levels.
This comprehensive therapy delivers benefits without adversely affecting blood pressure, liver function, or renal function. The company emphasizes that this integrated approach combining treatment, prevention, and metabolic management is exceptionally rare among current prostate medications and holds significant appeal for men aged 40 and above.
Technical Barriers and Competitive Advantages
Due to the inherent complexity and diversity of components in novel botanical drugs, quality control poses greater challenges compared to that of small-molecule chemical drugs. Jianyong Biotechnology asserts that the company has successfully established a comprehensive technical platform, which includes:
• Purification and establishment of reference standards.
• Development and validation of analytical methods.
• Perform the validation analysis and verification process.
The company believes that such comprehensive capabilities create substantial market entry barriers, rendering the products highly difficult to replicate. Furthermore, they effectively mitigate risks associated with competition from counterfeit and substandard products as well as generic drugs, ultimately contributing to an extended period of market monopoly.
The upgraded market positioning and strategic value
As a plant-based new drug protected by global patents, Jyong Biotech believes its market strategy leverages the following key advantages:
• Pricing competitiveness: Its unique metabolic protection profile and safety profile enable it to command higher prices compared to non-patented generic drugs, making it attractive to both out-of-pocket and high-end healthcare markets.
• Authorization potential: The combination of high tolerability, excellent safety profile (no serious adverse reactions), and multiple clinical benefits makes it an ideal target for international pharmaceutical collaboration.
• Market scalability: Expanding the product portfolio from treatment-oriented approaches to the fields of preventive medicine and health management.
Globally, over 500 million men aged 50 and above seek treatment for benign prostatic hyperplasia (BPH). In 2020, the global BPH drug market was valued at $4.1 billion and is projected to reach $9.8 billion by 2026. Although the current treatment market generates annual revenues of approximately $6.5 to $7 billion, this figure reflects price reductions due to patent expiration. If calculated based on prices during the patent period, the market potential exceeds $20 billion annually.
“Due to the complex composition of botanical new drugs, they face significant challenges in quality control compared to small-molecule chemical drugs,” stated Chairman Guo of Jianyong Biotechnology. “We have established a robust technical platform that encompasses the purification of reference standards, development and validation of analytical methods, as well as performance validation analyses. This high entry barrier makes counterfeiting difficult to achieve, reduces competition from generic drugs, and helps extend market exclusivity periods.”
Chairman Guo stated: “Botreso® is Taiwan’s first oral botanical drug to obtain an IND approval from the U.S. FDA for Phase III clinical trials (API-1) and has successfully completed all four Phase III clinical trials.”
Jyong Biotech holds multiple invention patents across Asia, the Americas, and the European Union, and has signed letters of intent and investment agreements with several international pharmaceutical companies. The company plans to further expand its strategic, fee-based licensing partnerships to support its global market expansion.
As of today, Botreso® and PCP remain in the investigational new drug candidate stage and have not yet been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on significant progress.
Company Profile: Jyong Biotech Ltd., headquartered in Taiwan, is a science-driven biotechnology company dedicated to the research, development, and commercialization of innovative and differentiated novel drugs (of plant origin), with a primary focus on the treatment of urinary system disorders, initially targeting the markets in the United States, the European Union, and Asia. Since its establishment in 2002, the company has developed comprehensive capabilities encompassing all critical stages of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging robust R&D capabilities and proprietary platforms, the company has developed a portfolio of plant-derived candidate drugs, including its lead plant-based candidate Botreso®, another plant-based candidate drug in clinical development, and several other plant-based candidates in preclinical stages. The company is committed to developing and delivering cutting-edge innovative therapeutics to address customer health needs and strives to become a respected and valuable enterprise.
For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com
Investor Relations Department
WFS Investor Relations Inc.
Mailbox: services@wfsir.com
Phone: +1628 283 9214
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Experience the Future of Urban Mobility Firsthand: Tarran Presents the New L1 Series at Eurobike 2026
United States, 16th Jul 2026, – As the global cycling industry gathers in Frankfurt from June 24 to 27, 2026, TARRAN will exhibit at Booth F12 B26, where the company will debut the new L1 Series alongside its flagship model, the T1 Pro. Visitors can experience both models firsthand at the booth.
Following last year’s market launch of the T1 Pro, Tarran is expanding its portfolio, combining engineering precision with the demands of everyday urban riding.
Featured Models
L1 Series: New for 2026
The new model is engineered for practical everyday use. As TARRAN’s first intelligent longtail cargo bike designed for families, its core innovations include the industry-first SyncStand Auto, an electronic kickstand that parks the bike at the push of a button, and an E-Dropper Post that adjusts saddle height instantly.
Paired with Enviolo AUTOMATIQ Pro automatic shifting, fully integrated into TarranOS, the L1 delivers an intuitive, low-effort riding experience. It features a 100 Nm mid-drive motor, a removable 693 Wh battery built with Samsung cells, and a reinforced longtail frame supporting a maximum gross vehicle weight of 215 kg (474 lb).
For rider and passenger safety, the Vision Unit—combining a rear-view camera and mmWave radar—works together with integrated front and rear turn signals to provide 360-degree protection for the whole family. TARRAN continuously improves the L1 through over-the-air updates, supporting long-term product maintenance and ongoing refinement. A firmware update scheduled for late June will add native control for DJI action cameras and an anti-pinch safety function for the electronic kickstand.
T1 Pro
Successfully launched last year, the flagship model continues to demonstrate the brand’s technological strengths. The T1 Pro is equipped with active safety systems that monitor the bike’s surroundings and assist the rider in critical situations.
The T1 Pro features Tarran’s proprietary Dynamic Dualdrive landing gear, which stabilizes the bike while riding and at a standstill, reducing the risk of tipping. It is designed to carry families with two to three children in comfort, while its compact 2.26-meter (7.4 ft) overall length ensures agile handling.
Putting the Riding Experience First
Tarran believes that genuine innovation is best understood through direct experience. While the exhibit offers a closer look at the underlying technical architecture, consumers and e-bike enthusiasts are welcome to test ride both models directly at the TARRAN booth.
Visitors can see for themselves how the intuitive controls and safety features change the riding experience in urban environments.
Global Growth and Dealer Network
Reflecting TARRAN’s continued growth, and with the L1 Series now in series production, the brand’s products are available in more than 100 retail stores worldwide.
Strengthening its global footprint, TARRAN is now formally entering the North American market, actively building a dealer network across the United States and Canada to bring its intelligent, safety-focused cargo bikes to more families.
Expert Dialogue and Consultations
Tarran offers trade journalists and partners the opportunity for individual, in-depth background briefings. On-site experts will be available in the following areas:
Product Development and Technology: Shiyuan, Product Manager.
Strategy and Marketing: Dennis Wang and Larry Hu.
DACH Region Sales: Sebastian Locher and Jiaming Lee.
Benelux Region Sales: Fabian Hard.
Press Contact and Scheduling: To arrange a briefing or a test ride, please contact tarran@laika.berlin.
About TARRAN
Founded in 2023, TARRAN develops human-centered mobility experiences that combine clean energy with intelligent systems, with the goal of accelerating the transition to a more sustainable future.
The team draws on experience from leading technology companies, including DJI, and believes that technology can help solve real-world challenges while making a positive contribution to the world we live in.
TARRAN currently operates across three locations: Dusseldorf, Hong Kong, and Shenzhen. Its research, development, and testing center is located in Shenzhen, while its manufacturing hubs are situated in Europe and Southeast Asia.
Media Contact
Organization: Tarran GmbH
Contact
Person: Media Relations
Website:
https://tarranbikes.com/
Email:
store@tarranbikes.com
Contact Number: 8618898353598
Country:United States
The post
Experience the Future of Urban Mobility Firsthand: Tarran Presents the New L1 Series at Eurobike 2026 appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Nova Junk marks 20 years of eco-friendly junk removal in the Washington DC area
Jyong Biotech has updated its market entry strategy for innovative botanical pharmaceuticals, establishing multiple competitive advantages for its new drug portfolio
Experience the Future of Urban Mobility Firsthand: Tarran Presents the New L1 Series at Eurobike 2026
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release1 week ago
Vincere Portfolios Highlights Growing Shift Toward Algorithmic Futures Trading Among Independent Investors
-
Press Release5 days ago
Thriving in Retirement Michael Masor’s Newly Released Book is a Complete Blueprint for Modern Retirement Planning
-
Press Release6 days ago
SK Hynix ETFs – 2x Long (SKHX) & 1x Short (SKHZ) from Leverage Shares by Themes Arrive as ADRs Begin Trading
-
Press Release6 days ago
Ruckaroo Launches World’s First Fitness App Built for Weighted Walking
-
Press Release5 days ago
New Guide Helps Musicians Create a Connected Music Marketing System
-
Press Release6 days ago
Dubai Health and Rush University System for Health Announce Strategic Collaboration to Advance Quality of Care
-
Press Release6 days ago
JDLINO BRAND & FELITWO Celebrating El Champ — The Feroz Vargas and His Familión: A New Era in Boxing Power
-
Press Release5 days ago
Northlake Concierge Medical Center Announces Boutique Class-A Medical Office Development in Tucker, Georgia